Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival
Hall et al.,
Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of Survival,
The Annals of Thoracic Surgery, doi:10.1016/j.athoracsur.2022.01.043
Retrospective 505 ECMO patients showing no significant difference in mortality in unadjusted results.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
risk of death, 11.2% lower, RR 0.89, p = 0.31, treatment 31 of 56 (55.4%), control 280 of 449 (62.4%), NNT 14.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Hall et al., 18 Feb 2022, retrospective, USA, peer-reviewed, 15 authors.
Abstract: Journal Pre-proof
Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO:
Predictors of Survival
Celeste A. Hall, Jeffrey P. Jacobs, MD, Alfred H. Stammers, MSA, James D. St.
Louis, MD, J.W. Awori Hayanga, MD, Michael S. Firstenberg, MD, Linda B. Mongero,
CCP, Eric A. Tesdahl, PhD, Keshava Rajagopal, MD, PhD, Faisal H. Cheema, MD,
Kirti Patel, CCP, Tom Coley, CCP, Anthony K. Sestokas, PhD, Marvin J. Slepian, MD,
Vinay Badhwar, MD
PII:
S0003-4975(22)00198-9
DOI:
https://doi.org/10.1016/j.athoracsur.2022.01.043
Reference:
ATS 36012
To appear in:
The Annals of Thoracic Surgery
Received Date: 7 November 2021
Revised Date:
18 December 2021
Accepted Date: 25 January 2022
Please cite this article as: Hall CA, Jacobs JP, Stammers AH, St. Louis JD, Hayanga JWA, Firstenberg
MS, Mongero LB, Tesdahl EA, Rajagopal K, Cheema FH, Patel K, Coley T, Sestokas AK, Slepian MJ,
Badhwar V, Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO: Predictors of
Survival The Annals of Thoracic Surgery (2022), doi: https://doi.org/10.1016/j.athoracsur.2022.01.043.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 by The Society of Thoracic Surgeons
Jo
na
ur
re
lP
ro
-p
of
Jacobs
Page 1 of 16
Multi-institutional Analysis of 505 COVID-19 Patients Supported with ECMO:
Predictors of Survival
Running Head: ECMO and COVID-19
aCeleste A. Hall, a,bJeffrey P. Jacobs, MD, bAlfred H. Stammers, MSA, cJames D. St. Louis, MD, dJ.W.
Awori Hayanga, MD, eMichael S Firstenberg, MD, bLinda B. Mongero, CCP, bEric A. Tesdahl, PhD,
fKeshava Rajagopal, MD, PhD, f,gFaisal H. Cheema, MD, bKirti Patel, CCP, bTom Coley, CCP,
of
bAnthony K. Sestokas, PhD, hMarvin J. Slepian, MD, dVinay Badhwar, MD
aUniversity of Florida, Gainesville, FL; bMedical Department, SpecialtyCare, Inc., Nashville, TN ;
ro
cChildren Hospital of Georgia, Augusta, Georgia; dWest Virginia University, Morgantown, WV; eSt
-p
Elizabeth Medical Center, Appleton, Wisconsin; fUniversity of Houston, Houston, TX; gHCA Research
lP
re
Institute, Nashville, TN; hUniversity of Arizona, Tucson, AZ
ur
na
Presented at the Sixty-eighth Annual Meeting of the Southern Thoracic Surgical Association, Atlanta,
GA, Nov 3-6, 2021.
Keywords: Extracorporeal Membrane Oxygenation, Coronavirus, COVID-19, Pulmonary failure,
Jo
acute respiratory distress syndrome
Words: 4,496/4500
Corresponding Author: Jeffrey P. Jacobs, University of Florida, 1600 SW Archer Rd, Gainesville,
Florida; jeffjacobs@msn.com
Jacobs
Page 2 of 16
Abstract
Background:
We reviewed our experience with 505 patients with confirmed COVID-19
supported with ECMO at 45 hospitals and estimated risk factors for mortality.
Methods:
A multi-institutional database was created and utilized to assess all patients with
COVID-19 who were supported with ECMO. A Bayesian mixed-effects logistic regression model was
estimated to assess the effect on survival of days between COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit